FDA Approves Otarmeni: The Gene Therapy That Gives Hearing to Children Born Deaf
On April 23, 2026, the FDA granted full approval to Otarmeni (DB-OTO), Regeneron's gene therapy for hereditary deafness caused by mutations in the OTOF gene — making it the first approved gene therapy specifically targeting congenital hearing loss in the United States.
The approval follows results from the CHORD clinical trial that were described by FDA reviewers as "among the most compelling outcomes ever observed in a gene therapy trial for a sensory disorder." Children who had been profoundly deaf from birth — who had never experienced sound — developed functional hearing after a single treatment.
Understanding OTOF-Related Deafness
The inner ear contains approximately 15,000 specialized cells called hair cells — sensory cells that convert sound vibrations into electrical signals that travel along the auditory nerve to the brain. This conversion process requires a protein called otoferlin, encoded by the OTOF gene.
In children with OTOF gene mutations, the hair cells are present and structurally normal — but they cannot produce functional otoferlin. Without otoferlin, the hair cells cannot release neurotransmitters in response to sound, and the auditory signal never reaches the brain. The result is profound congenital deafness despite a structurally intact inner ear.
This condition is called DFNB9, or otoferlin deficiency hearing loss. It accounts for approximately 2-8% of cases of hereditary deafness — globally, tens of thousands of children born each year.
Before Otarmeni, children with OTOF-related deafness had one primary therapeutic option: cochlear implants, which bypass the non-functional hair cells entirely by electrically stimulating the auditory nerve. Cochlear implants work — they enable speech perception and language development — but require surgery, external hardware, and ongoing management.
How Otarmeni Works
Otarmeni delivers a functional copy of the OTOF gene directly to the cochlear hair cells using an adeno-associated virus (AAV1) vector — a modified, non-pathogenic virus that serves as a delivery vehicle for genetic cargo.
The treatment is administered through a single injection into the cochlea (the inner ear) during a surgical procedure. The AAV1 vector infects cochlear hair cells and deposits the functional OTOF gene, which the cells then use to produce otoferlin. With otoferlin present, the hair cells can respond to sound normally, releasing neurotransmitters and activating the auditory nerve.
The key advantage over cochlear implants: Otarmeni aims to restore the hair cells' natural function rather than bypassing them. In children where treatment succeeds, the result is hearing that uses the ear's own biological machinery — not an electronic prosthesis.
The CHORD Trial: What Happened When Children Heard for the First Time
The CHORD trial enrolled children ages 1-6 with confirmed OTOF gene mutations and bilateral profound deafness. The primary endpoint was hearing threshold improvement — measured by ABR (auditory brainstem response) testing, which measures the brain's electrical response to sound.
The results, which became an emotional landmark in clinical trials:
86% of treated children developed measurable hearing on ABR testing within 4-12 weeks of treatment.
Median hearing threshold improvement: 73 decibels — meaning children who previously required sounds louder than a jet engine to register any response could, after treatment, hear sounds as quiet as normal conversation.
Speech perception: Children who received treatment developed speech perception scores that, at 6-month follow-up, were comparable to age-matched peers using cochlear implants — and in some cases exceeded cochlear implant outcomes.
Language development: Several children who had never heard speech began acquiring spoken language milestones after treatment, including first words and phrases — a development that, given their pre-treatment profound deafness, was not expected without intervention.
Most watched moment: Video footage from the trial showing a 2-year-old child responding to her mother's voice for the first time — turning her head, reaching toward the sound source, smiling — became one of the most shared medical trial videos in recent memory.
The Significance Beyond One Condition
The Otarmeni approval matters far beyond the specific population of children with OTOF mutations.
It validates the inner ear as a gene therapy target. The cochlea is anatomically accessible, relatively isolated (the blood-labyrinth barrier limits systemic spread of AAV vectors), and contains a defined population of cells with a clear therapeutic target. These properties make it an ideal gene therapy site. Otarmeni's success will accelerate development of gene therapies for other forms of hereditary hearing loss — dozens of other genes have been implicated in congenital deafness.
It demonstrates that sensory organs can be addressed by gene therapy. Gene therapies have previously shown efficacy in inherited blindness (Luxturna for RPE65 mutations) and are in development for multiple other ocular conditions. Otarmeni extends this to hearing, suggesting a broader sensory gene therapy landscape.
It challenges the cochlear implant paradigm. Cochlear implants have been the standard of care for profound congenital deafness for decades. They work well, but they are electronic prostheses, not biological restoration. For the OTOF-related population, gene therapy now offers an alternative that uses the ear's own biology. How this affects decision-making for families, cochlear implant timing, and implant manufacturers is a significant question.
What Comes Next: Expanding the Gene Therapy Approach
Regeneron is already in trials for gene therapies targeting other genetic causes of hearing loss. Several academic medical centers are in early-stage trials for GJB2 (connexin 26) mutations — the most common single-gene cause of hereditary deafness, accounting for 15-30% of all cases.
If gene therapies can be developed for GJB2 and other common deafness genes, the population addressable by this approach grows from tens of thousands to potentially millions globally.
The FDA's Otarmeni approval signals regulatory willingness to support this development pathway — a strong signal for continued investment in inner ear gene therapy research.
Impact Table
| Metric | CHORD Trial Result |
|---|---|
| Patients enrolled | 32 |
| Hearing improvement (any) | 86% |
| Median threshold improvement | 73 dB |
| Speech perception at 6 months | Comparable to cochlear implant |
| Serious adverse events | 2 (resolved) |
| Treatment | Single injection, one-time |
